Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy

M Tan, R Appleton

Attention deficit hyperactivity disorder (ADHD) is characterised by inattention, impulsivity, and hyperactivity. The DSM-IV diagnosis of ADHD requires the presence of six of nine items or features that must have been present for at least six months, to have had an onset before 7 years of age, and to have resulted in significant distress or impairment. In the general population, the prevalence of ADHD is approximately 5%. There is a high co-morbidity of epilepsy and attentional and behavioural problems, including ADHD, and it has been estimated that at least 20% of patients with epilepsy may present with features of ADHD.

Methylphenidate, a psychostimulant and derivative of amphetamine, is a controlled drug that is recommended for use as part of a treatment programme for children with a confirmed diagnosis of attention deficit hyperactivity disorder (ADHD). The drug is reported to be effective in up to three quarters of children with ADHD and is generally associated with few side effects. However, there is a belief that methylphenidate may lower seizure threshold and consequently concerns have been raised regarding the use of the drug in children who have ADHD and epilepsy. This predominantly reflects the authors’ personal experience from discussions with colleagues in community and child and adolescent mental health but also reflects statements within commonly used prescribing manuals, including Medicines for Children (published by the Royal College of Paediatrics and Child Health, 2003, pp. 403–4). Both the British National Formulary (BNF, September 2003, pp. 197–8) and the Monthly Index of Medical Specialities (MIMS, October 2003, pp. 122–3) recommend caution when prescribing psychostimulants, including dexamphetamine and methylphenidate, to patients with epilepsy, and discontinuation of these drugs if seizures occur. Given the relatively common co-occurrence of epilepsy and ADHD, this is a potentially important issue.

The aim of this article is to briefly review the relation between ADHD and epilepsy, and to address the use of methylphenidate in children with both epilepsy and ADHD. It is not within the remit or scope of this article to discuss either the differentiation of ADHD from conditions such as oppositional defiant disorder and conduct disorder or the complex relation between cognitive (including attentional) and behavioural problems and epilepsy. Comprehensive reviews of this relation can be found in recent publications. Clearly, implicit within this review is the assumption that the diagnosis of ADHD is both appropriate and accurate.

ADHD AND EPILEPSY

Many hypotheses have been put forward in an attempt to explain the co-existence of or apparent association between ADHD and epilepsy. Attention deficit hyperactivity disorder and epilepsy may exist within a common syndrome complex; both may have a genetic predisposition; and finally, antiepileptic drugs (AEDs) may contribute to both attentional difficulties and increased levels of activity, including irritability in a number of children. The observation that behavioural and attentional problems may be seen prior to the onset of epilepsy would suggest that they are unlikely to be the direct effect of clinical seizures or AEDs. A recent study of 51 schoolchildren showed no deficits in attention in children with newly diagnosed idiopathic or cryptogenic epilepsy. Most studies seem to suggest that the majority of AEDs (other than possibly phenobarbitone and the benzodiazepines) have little effect on cognitive functioning, including attention.

The type of epilepsy may also be important, although the evidence is conflicting. Children with complex partial seizures are reported to have significant difficulty with aspects of sustained attention, irrespective of whether there is a preceding or concurrent diagnosis of ADHD. Although children with ADHD and those with complex partial seizures have similar problems with attention, the mechanism responsible may be different. Impaired attention has also been described in children with benign childhood epilepsy with centro-temporal (rolandic) spikes (BECTS). Right sided interictal epileptiform activity in these children interferes with right hemispheric activity including attention. Other studies have suggested that the seizure or epilepsy type is not important. Williams et al found a statistically significant reduction in visual and verbal attention in 79 children with active and treated epilepsy that was irrespective of seizure type, suggesting a possible general developmental effect of epilepsy or its treatment, or both. More recently Dunn and colleagues found that 64 of 175 (36%) children with

Abbreviations: ADHD, attention deficit hyperactivity disorder; AED, antiepileptic activity; CAE, childhood onset absence epilepsy; EEG, electroencephalogram
epilepsy met DSM-IV criteria for ADHD and that although neither seizure type nor focus of electroencephalographic (EEG) discharge predicted the occurrence of ADHD, there was a tendency for ADHD to occur more frequently in those with generalised seizures.

Clearly, children with childhood onset absence epilepsy (CAE) may present with poor attention or concentration because of frequent seizures. It has been our experience (and one that is likely to be shared by others) that a number of children with CAE have been wrongly diagnosed as having ADHD. However, the diagnosis of CAE should be obvious from the history, including (typically) being able to induce an absence seizure during hyperventilation undertaken in the outpatient clinic. In addition, and in contrast to ADHD, most children with CAE are girls and impulsivity/hyperactivity rarely complicates this specific epilepsy syndrome.

Electroencephalography has also been reported to be abnormal in children with ADHD, some showing epileptiform activity. The reported incidence ranges from 6.1% of 476 of children with ADHD (compared to 3.5% of 3726, normal, school age children),6 to 30.1% of 176 children with ADHD.18 In this latter study, EEG recordings showed predominantly focal rather than generalised spike and wave complexes.16 Holtman et al reported that the frequency of centro-temporal (rolandic) spikes in children with ADHD was significantly higher than expected from normal children, based on epidemiological studies (5.6% versus 2.4% respectively),19 and have therefore suggested that all children being evaluated for a possible diagnosis of ADHD should undergo EEG, irrespective of whether they have experienced any epileptic seizures.20 The authors make no comment on whether and how they would further investigate and treat children with rolandic spikes and ADHD.

Finally, although children with EEG abnormalities who do not have epilepsy are assumed to be at risk of developing seizures, there are insufficient data to support this hypothesis.21

**IS METHYLPHENIDATE EFFECTIVE AND SAFE IN CHILDREN WITH ADHD AND EPILEPSY?**

There is little or no published data to suggest that psychostimulants, including methylphenidate, contribute to the de novo development of epilepsy or exacerbate seizures in children with an established diagnosis of epilepsy. Such an association would be unexpected for a number of reasons. Firstly, a new development of epilepsy or an exacerbation of pre-existing epilepsy and the use of methylphenidate may be entirely coincidental, reflecting the natural history of the epilepsy in any individual. Secondly, methylphenidate may interfere with sleep and as a consequence, the drug may lower the threshold for epileptic seizures resulting in deterioration in seizure control. Thirdly, based on what is still a limited understanding of why an epileptic seizure starts (and stops) spontaneously, there is no reason to believe that methylphenidate should be pro-convulsant and therefore lower seizure threshold. The drug primarily acts on the presynaptic reuptake of the neurotransmitters noradrenaline and dopamine rather than the neurotransmitters commonly associated with the pathophysiology of seizures (gamma aminobutyric acid (GABA), glutamic and aspartic acids). It is not known to affect calcium or sodium channels, which are also implicated in the pathophysiology of many of the epilepsies. Finally, although methylphenidate may inhibit the metabolism of phenobarbitone, primidone, phenytoin, and ethosuximide (ETX), this is unlikely to have any significant clinical impact as these drugs are only very rarely (or occasionally in the case of ETX), used in the long term treatment of epilepsy in children. There is little or no information on whether it interacts significantly with the newer antiepileptic drugs. None of these theoretical mechanisms represent a direct effect of methylphenidate on epilepsy.

There is considerable anecdotal evidence to suggest that methylphenidate is safe in children whose seizures are well controlled with antiepileptic drugs. Feldman et al, in evaluating 10 patients with epilepsy who were seizure-free and who also had ADHD, found that methylphenidate was effective in treating the ADHD symptoms in the majority, and none of the patients experienced seizures during the 10 week study period.22 All patients had abnormal baseline EEGs that did not alter significantly during the study period.23 Gross-Tsur et al studied 30 children who had active seizures before starting methylphenidate. The 25 children who were seizure-free following antiepileptic medication remained seizure-free, but the remaining five who had ongoing seizures showed no significant increase in seizure frequency during the four month study.

Gucuyener et al examined the safety and efficacy of methylphenidate in the management of two groups of patients with ADHD: one with epilepsy and one without epilepsy but with EEG abnormalities.24 One hundred and nineteen children were followed up for 12 months. Methylphenidate was effective in controlling ADHD symptomatology in both groups. No seizures were observed in those with ADHD and epileptiform abnormalities on EEG. There was also no significant change in mean seizure frequency in the group with active epilepsy. In addition, the EEG improved, including becoming normal, in many patients after receiving methylphenidate. This finding is consistent with that of an earlier study reporting EEG findings in children before and six months after commencing stimulant therapy.25

In contrast, Hemmer and colleagues26 reported different findings in their study of 234 children with ADHD but without epilepsy who underwent EEG examination prior to starting methylphenidate. Following the introduction of methylphenidate, three of the 30 children with an epileptiform EEG developed seizures. The incidence in those with centro-temporal (rolandic) spikes was higher at 16.7%. The incidence of seizures was only 0.6% in the group who did not have epileptiform EEGs. Although the authors concluded that epileptiform EEGs in neurologically normal children with ADHD could predict the “eventual occurrence of seizure”, this risk cannot (and should not) necessarily be attributed to the use of the drug.27 Other retrospective data published in abstract form28 have also reported the beneficial use of methylphenidate in those with ADHD and epilepsy. McBride and colleagues29 reported a trend towards a lower incidence of seizures in those patients with traumatic brain injury and epilepsy. McBride and colleagues29 found that none of their 23 children with a prior history of seizures (n = 20) or epileptiform abnormalities on EEG (n = 3) and who were treated with methylphenidate, showed any seizure exacerbation or developed new seizures for up to four years after receiving the drug.

In summary, most studies have shown that methylphenidate improves symptoms of ADHD and enhances the performance in children with both ADHD and epilepsy. It does not appear to exacerbate seizures in children with either well controlled or active epilepsy. There is conflicting evidence as to whether seizures occur more frequently in those without epilepsy but who have abnormal EEG abnormalities. The presence or absence of rolandic spikes on the EEG in children with a diagnosis of ADHD are of uncertain clinical significance and should not, in isolation, be used to refute a clinical diagnosis of ADHD. It is also important to emphasise that the accurate interpretation of any EEG depends on obtaining a successful recording that is as
artefact-free as possible (and that any artefacts are correctly identified) and knowledge of both the normal maturational development of the EEG during early childhood as well as the recognition of genuine abnormalities. This is often difficult in view of the age and behavioural characteristics of this specific population and potentially limited expertise of those undertaking and reporting EEGs in young children. Finally, the definition of “epileptiform” activity on EEG varies between studies. These practical and experiential difficulties may in part explain the reported different EEG findings in children with ADHD. This emphasises the importance of diagnosing ADHD on the basis of clinical criteria and by medical and psychological staff who are experienced in the diagnosis and management of childhood behavioural disorders.

Clearly, the literature appraised and evidence cited in this brief review are largely anecdotal and not based on randomised clinical trial data. In addition, any conclusions or recommendations will obviously be dependent on accurate and consistent diagnoses of both ADHD and epilepsy.

CONCLUSION

There is no published evidence to suggest that either the short or long term treatment with methylphenidate increases the risk of developing seizures in children with ADHD. Studies to date have also suggested that methylphenidate would appear to be safe to use in children who have active or well controlled epilepsy. There is little or no evidence indicating that the drug interacts significantly with the more commonly prescribed antiepileptic drugs. Finally, there is insufficient evidence to justify undertaking an EEG in all children with an obvious clinical diagnosis of ADHD and without epilepsy prior to administration of methylphenidate. Where an EEG is inappropriately undertaken without a clinical diagnosis of epilepsy, any abnormalities identified on the EEG must be interpreted appropriately and should not influence the treatment of ADHD.

Although there is no identified contraindication to the use of methylphenidate in children with pre-existing epilepsy, it would clearly be important to monitor seizure frequency in the first few weeks and months after prescribing this stimulant drug.

REFERENCES

Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy

M Tan and R Appleton

Arch Dis Child 2005 90: 57-59
doi: 10.1136/adc.2003.048504

Updated information and services can be found at:
http://adc.bmj.com/content/90/1/57

These include:

References
This article cites 24 articles, 3 of which you can access for free at:
http://adc.bmj.com/content/90/1/57#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Attention-deficit hyperactivity disorder (93)
Child and adolescent psychiatry (paediatrics) (683)
Epilepsy and seizures (391)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/